Lupin Ltd (LUPIN) – Company Profile and SWOT Analysis

Lupin Ltd (LUPIN) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

rLupin Ltd (Lupin) is a pharmaceutical company primarily engaged in the development and distribution of a diverse range of healthcare products. The company's portfolio includes products with a focus on generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. Lupin's products cater to various therapeutic areas such as anti-tuberculosis, diabetes, cardiovascular, respiratory, women's health, and the central nervous system. The company offers generic medicines related to anti-TB, diabetes, cardiovascular, respiratory, and ophthalmic. Its biosimilar products include Filgrastim, Peg-Filgrastim, and Etanercept, and specialty products are focused on women's health and rare neurological disorders. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company has its manufacturing units in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Scope

• Detailed information on Lupin Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Lupin Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Lupin Ltd including a breakdown and examination of key business segments

• News about Lupin Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Lupin Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Lupin Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Lupin Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Lincoln Pharmaceuticals Ltd

Divi's Laboratories Ltd

Intas Pharmaceuticals Ltd

Dr. Reddy's Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Aarti Drugs Ltd

Cipla Ltd

Abbott India Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Lupin Ltd - Key Facts

Lupin Ltd - Key Employees

Lupin Ltd - Key Employee Biographies

Lupin Ltd - Major Products and Services

Lupin Ltd - History

Lupin Ltd - Company Statement

Lupin Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Lupin Ltd - Business Description

Business Segment: Others

Overview

Performance

Business Segment: Pharmaceuticals

Overview

Performance

Geographical Segment: India

Performance

Geographical Segment: Others

Performance

Geographical Segment: USA

Performance

R&D Overview

Lupin Ltd - Corporate Strategy

Lupin Ltd - SWOT Analysis

SWOT Analysis - Overview

Lupin Ltd - Strengths

Lupin Ltd - Weaknesses

Lupin Ltd - Opportunities

Lupin Ltd - Threats

Lupin Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025

Lupin Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Aug 05, 2025: Lupin Reports Financial Performance for Quarter Ending June 30, 2025

Jul 17, 2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)

Jul 17, 2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015 (‘SEBI Listing Regulations’)

Jul 17, 2025: Lupin Achieves GMP Certification From TGA Australia for Dabhasa API Facility

Jul 10, 2025: Lupin and Zentiva in licence and supply deal for Certolizumab Pegol

Jun 05, 2025: Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

May 15, 2025: Lupin Appoints Punita Lal as Additional Director

May 14, 2025: Lupin Announces Financial Performance for Quarter and Fiscal Year Ending March 31, 2025

May 14, 2025: Lupin : Change in Directorate

Apr 23, 2025: Lupin Diagnostics Achieves NABL Accreditation for All Greenfield Labs

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Lupin Ltd, Key Facts

Lupin Ltd, Key Employees

Lupin Ltd, Key Employee Biographies

Lupin Ltd, Major Products and Services

Lupin Ltd, History

Lupin Ltd, Subsidiaries

Lupin Ltd, Key Competitors

Lupin Ltd, Ratios based on current share price

Lupin Ltd, Annual Ratios

Lupin Ltd, Annual Ratios (Cont…1)

Lupin Ltd, Annual Ratios (Cont…2)

Lupin Ltd, Interim Ratios

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025

Lupin Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Lupin Ltd, Performance Chart (2021 – 2025)

Lupin Ltd, Ratio Charts

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports